Voyager Posts Encouraging Preclinical Data For CNS-Directed Gene Therapy

by Vandana Singh, Benzinga Editor

October 20, 2021 9:27 AM | 1 min read |

Voyager Therapeutics Inc VYGR has announced the presentation of preclinical data of GBA1 gene replacement therapy.
The data demonstrated that a single intravenous (IV) dose of GBA1 gene replacement therapy achieved widespread distribution in the central nervous system (CNS) and peripheral tissues and substantially raised levels of the GCase enzyme in animal models.
The results were presented at the European Society of Gene and Cell Therapy (ESGCT).
The increase over endogenous GCase levels in the range of 300% - 660% suggested a promising rise in GCase levels of 30% - 50% that is anticipated to be clinically impactful.
Price Action: VYGR shares up 1.09% at $4.64 during the premarket session on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care General Briefs gene therapy Preclinical Phase

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.